Initial Approach to Treating Secondary Membranous Nephropathy
Identification and Treatment of Underlying Cause
- The initial approach to treating secondary membranous nephropathy should focus on identifying and treating the underlying cause while providing optimal supportive care, with immunosuppressive therapy decisions based on disease severity and kidney function stability, as recommended by the Kidney International guidelines 1
Supportive Care
- All patients with secondary membranous nephropathy and proteinuria should receive optimal supportive care, including RAS blockade (ACEi/ARB), blood pressure control, and management of nephrotic syndrome complications, according to the Kidney International and Praxis Medical Insights guidelines 1, 2
- Immunosuppressive therapy is not required in patients with proteinuria < 3.5 g/d, serum albumin > 30 g/L, and eGFR > 60 ml/min per 1.73 m², as stated in the Kidney International guidelines 3
- Prophylactic anticoagulation should be considered in patients with severe hypoalbuminemia (<25 g/L by bromocresol purple or <20 g/L by bromocresol green) due to increased thromboembolism risk, as recommended by the Kidney International and Praxis Medical Insights guidelines 3, 2
Immunosuppressive Therapy Based on Disease Severity
- If immunosuppressive therapy is indicated (proteinuria >3.5 g/d or complications of nephrotic syndrome), consider calcineurin inhibitors (CNIs) as first-line therapy, according to the Kidney International guidelines 1
- Rituximab may be considered as an alternative first-line agent in patients with stable kidney function, as stated in the Kidney International guidelines 1
- Cyclophosphamide with glucocorticoids is recommended as first-line therapy when kidney function is declining, with a cumulative dose not exceeding 36 g, as recommended by the Kidney International guidelines 1
Treatment Monitoring and Adjustment
- If proteinuria persists while serum albumin has increased, consider secondary focal segmental glomerulosclerosis (FSGS), as stated in the Kidney International guidelines 1
- In patients with persistent proteinuria despite appropriate treatment of the underlying cause, a repeat kidney biopsy may be considered to document active disease, according to the Kidney International guidelines 1
Management of Resistant Disease
- For patients resistant to initial therapy with stable eGFR, consider switching from CNIs to rituximab or vice versa, as recommended by the Kidney International guidelines 1
- For resistant disease with declining eGFR, cyclophosphamide with glucocorticoids is recommended, according to the Kidney International guidelines 1
Special Considerations for Lupus Membranous Nephropathy
- For patients with lupus nephritis Class V (membranous) with or without proliferative components, treatment with glucocorticoids plus one of the following is recommended: mycophenolic acid analogs, low-dose intravenous cyclophosphamide, belimumab combined with either mycophenolic acid or cyclophosphamide, or mycophenolic acid with a calcineurin inhibitor, as stated in the Kidney International guidelines 5
Common Pitfalls to Avoid
- Using cyclophosphamide at doses that exceed the recommended cumulative limits, increasing the risk of malignancy and infertility, as warned by the Kidney International guidelines 1
- Continuing immunosuppression unnecessarily when disease is in remission, as cautioned by the Praxis Medical Insights guidelines 4
- Interpreting persistent proteinuria alone as treatment failure, as proteinuria may persist for months after immunologic remission, as noted by the Praxis Medical Insights guidelines 4